Elunate Drug Interactions

Pharmacokinetic Interactions: No dose adjustment is required when fruquintinib is used in combination with CYP3A inhibitors (refer to Pharmacology under Actions).
The combination of fruquintinib with moderate or strong CYP3A inducers reduces the exposure to fruquintinib, avoid concomitant use of moderate or strong CYP3A inducers. Alternative treatment with weak CYP3A inducing properties should be considered (refer to Pharmacology under Actions).
Based on in vitro studies, no inhibitory effect was observed with fruquintinib on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5 and no induction was observed with fruquintinib on CYP1A2, CYP2B6, or CYP3A4.
Fruquintinib inhibits efflux transporter P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), when concomitant use fruquintinib with P-gp and BCRP substrates, monitor patients more closely for any adverse reactions and make appropriate dose adjustments of the concomitant medications when necessary.
Fruquintinib can be used concomitantly with gastric acid reducing agents without any restrictions (refer to Pharmacology under Actions).